Sequence-specific alterations of epitope production by HIV protease inhibitors.

Sequence-specific alterations of epitope production by HIV protease inhibitors.
复制标题

DOI:
10.4049/jimmunol.1302805
复制
发表时间:
2014-04-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
通讯作者:
Le Gall S
Le Gall S
中科院分区:
其他
文献类型:
--
作者:
Kourjian G;Xu Y;Mondesire-Crump I;Shimada M;Gourdain P;Le Gall S

文献摘要

参考文献

被引文献

相似文献

细胞内蛋白酶和肽酶的抗原加工和表位呈递是CD8+ T淋巴细胞识别病原体感染细胞的关键。第一代HIV蛋白酶抑制剂(pi)改变蛋白酶体活性,但第一代或第二代pi对其他细胞肽酶的影响,潜在的机制以及对抗原加工和表位呈递CTL的影响尚不清楚。在这里,我们证明了几种HIV pi不仅改变了PBMC中的蛋白酶体,还改变了氨基肽酶的活性。利用PBMC细胞质提取物的体外降解实验,我们发现PIs以序列特异性的方式改变了寡肽的降解模式和肽的产生,增强了某些残基的裂解,减少了其他残基的裂解。PIs影响了多肽对细胞内降解的敏感性,改变了细胞内产生的HIV表位的动力学和数量。因此,在pi存在的情况下,传入病毒粒子的内源性降解导致ctl介导的hiv感染细胞杀伤的变化。通过以序列特异性的方式改变宿主蛋白酶活性和蛋白质降解模式,HIV pi可能使MHC-I向CTL呈递的肽多样化,改变CTL反应的模式,并可能为CTL介导的感染、癌症或其他免疫疾病中异常细胞的清除提供一种补充方法。
Antigen processing by intracellular proteases and peptidases and epitope presentation are critical for recognition of pathogen-infected cells by CD8+ T lymphocytes. First generation HIV protease inhibitors (PIs) alter proteasome activity, but the effect of first or second generation PIs on other cellular peptidases, the underlying mechanism and impact on antigen processing and epitope presentation to CTL are still unknown. Here we demonstrate that several HIV PIs altered not only proteasome but also aminopeptidase activities in PBMC. Using an in vitro degradation assay involving PBMC cytosolic extracts we showed that PIs altered the degradation patterns of oligopeptides and peptide production in a sequence-specific manner, enhancing the cleavage of certain residues and reducing others’. PIs affected the sensitivity of peptides to intracellular degradation, altered the kinetics and amount of HIV epitopes produced intracellularly. Accordingly the endogenous degradation of incoming virions in the presence of PIs led to variations in CTL-mediated killing of HIV-infected cells. By altering host protease activities and the degradation patterns of proteins in a sequence-specific manner, HIV PIs may diversify peptides available for MHC-I presentation to CTL, alter the patters of CTL responses, and may provide a complementary approach to current therapies for the CTL-mediated clearance of abnormal cells in infection, cancer or other immune disease.
DOI: 10.4049/jimmunol.0803663
发表时间: 2009-11-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者:
Hearn A;York IA;Rock KL
通讯作者: Rock KL
DOI: 10.4049/jimmunol.174.12.7524
发表时间: 2005-06-15
影响因子: 4.4
作者:
Feeney, ME;Tang, YH;Goulder, PJR
通讯作者: Goulder, PJR
DOI: 10.1016/j.ab.2004.02.007
发表时间: 2004-06-01
影响因子: 2.9
作者:
Batchelor, RH;Zhou, MJ
通讯作者: Zhou, MJ
DOI: 10.1097/00126334-200304010-00005
发表时间: 2003-04-01
影响因子: 3.6
作者:
Cardiello, PG;Monhaphol, T;Phanuphak, P
通讯作者: Phanuphak, P
DOI: 10.3324/haematol.2011.049981
发表时间: 2012-07-01
期刊: HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
影响因子: --
作者:
Bono, Camille;Karlin, Lionel;Arnulf, Bertrand
通讯作者: Arnulf, Bertrand